BIIB080, an investigational therapy for Alzheimer’s disease, was safe and well-tolerated, and sustainably lowered patients’ levels of tau —…
Articles by Forest Ray PhD
Annovis Bio is seeking orphan drug status for its investigational therapy ANVS401, known as Posiphen, for treating Alzheimer’s disease…
Donanemab showed an ability to slow cognitive decline and the loss of daily life abilities in people at earlier stages…
Non-invasive neurostimulation given to people with mild-to-moderate Alzheimer’s disease significantly and safely slowed their rate of functional and cognitive decline, meeting…
The U.S. Food and Drug Administration (FDA) found “deficiencies” that preclude discussing further steps in the approval process for Nuplazid…
The U.S. Food and Drug Administration (FDA) has extended its review period for aducanumab (BIIB037), an investigational therapy for…
A recent report found deep social inequalities in U.S. counties with the highest Alzheimer’s rates among Blacks and Latinos. Inequalities…
A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer’s disease to test IGC-AD1, an investigational…
The National Institute on Aging, a division of the National Institutes of Health, is awarding a $1.76 million, one-year…
A specific form of the tau protein, called phosphorylated-tau-217 or p-tau217, may function as a blood biomarker of Alzheimer’s disease,…